Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AZD4956

Small molecule · Inhibitor of DNA polymerase theta (pol theta) helicase domain (POLQ) · developed by ASTRAZENECA

Phase 1/2 Most advanced trial
AZN Developer

What is AZD4956?

AZD4956 is an orally bioavailable inhibitor that binds the helicase domain of DNA polymerase theta, blocking theta-mediated end joining repair of DNA double-strand breaks. It is being studied in solid tumours, particularly homologous recombination-deficient cancers that depend on this repair pathway.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
DNA polymerase theta (pol theta) helicase domain (POLQ)
Mechanism
Inhibitor of DNA polymerase theta (pol theta) helicase domain (POLQ)
Pathways
theta-mediated end joining (TMEJ) DNA double-strand break repair, apoptosis
Therapy area
Oncology
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

Conditions studied

Solid Tumours

More from ASTRAZENECA

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind AZD4956

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.